Antibiotic Developers Stocks19-01-2024 20:01:00 PM
The list of companies include PRTK-Paratek Pharmaceuticals Inc., SPRO-Spero Therapeutics Inc, MRK-Merck & Co Inc, SMMT-Summit Therapeutics Inc
* Latest intraday update before market close @ 19:45:45 PM 04/19/2024
Average return is down -1.7%
Median return is down -2.1%
1 out of 3 stocks are up (limited to those with intraday pricing feeds).
Top Movers
SPRO -3.4%SMMT -2.1%MRK + 0.5%

Aggregated price index with volume information


  • Antibiotic Developers stocks down 1.5% on average while median return down 0.3% in a day
  • Antibiotic Developers stocks down 6.5% on average while median return down 4.5% in a week
  • Antibiotic Developers stocks down 7.1% on average while median return down 8.6% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks
PE Ratio
P/B (mrq)
P/S (ttm)
Earning Growth
Short %
Held By Institutions %
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
877.741.377.204.04-1%318.6B1%75%49\-/Above resistance1940.0%
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
Detail Performance Summary
  • 1M winners are : Winners for past month are $MRK 1.6%
  • 1M losers are : Losers for past month are $SPRO -20.5%
  • 1W winners are : Winners for past week are
  • 1W losers are : Losers for past week are $SPRO -14.6%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 0.0%, for the past 3 months is 6.3%

In the past month for a 5 days rolling window, the highest corrrelation is 50.1%, the lowest correlation is -26.9%, the latest correlation is 38.8%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 28.8% between SMMT and SPRO

The lowest correlation is -24.4% between MRK and PRTK

Stock news

    In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According to Analysts. The US stock market is going through a pullback as optimism around rate cuts fades. The AI-led rally that boosted […]

    MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

    MIAMI, April 10, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S. Yang, Chi

    Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden’s efforts to steer the economy through inflation concerns are showing strong results. Recent data indicates a healthy economic position, with significant GDP growth outpacing other developed nations. Despite fluctuations in inflation and interest rates, the U.S. labor market remains resilient, adding jobs at a rapid pace. The country’s economic resilience, bolstered by substantial fiscal s

    In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

    A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

    In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024 in the red, driven by rising treasury yields, broader volatility and uncertainty around rate cuts […]

    The company was a standout in the biotech field, rising by nearly 23% over the period.

    Insiders who purchased Summit Therapeutics Inc. ( NASDAQ:SMMT ) shares in the past 12 months are unlikely to be deeply...

    MIAMI, March 22, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central European Time. The posters will also be made available on our website after